Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11026540rdf:typepubmed:Citationlld:pubmed
pubmed-article:11026540lifeskim:mentionsumls-concept:C0014432lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0017755lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0034255lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0007382lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:11026540lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:11026540pubmed:issue9lld:pubmed
pubmed-article:11026540pubmed:dateCreated2001-1-8lld:pubmed
pubmed-article:11026540pubmed:abstractTextThe discovery of the first class of potent glucose-6-phosphatase catalytic site inhibitors, substituted 4,5,6,7-tetrahydrothieno[3,2-c]- and -[2,3-c]pyridines, is described. Optimisation of this series involved solution phase combinatorial synthesis and very potent compounds were prepared with IC50 values down to 140 nM. The structure activity relationship (SAR) of these compounds indicates that: a tetrahydrothieno[3,2-c]pyridine core ring system and the isomeric [2,3-c] system are equipotent and much better than the corresponding benzo analogue, 1,2,3,4-tetrahydro-isoquinoline. The 4-substituent of the tetrahydrothieno[3,2-c]pyridine ring has to be a phenyl group, optionally substituted with a lipophilic 4-substituent, such as trifluoromethoxy or chloro. The 5-substituent of the tetrahydrothieno[3,2-c]pyridine ring has to be a substituted benzoyl; anisoyl and (E)-3-furan-3-ylacryloyl are the best of the investigated groups. Substitution in the benzoyl ortho position seems to be forbidden, whereas substitution in the meta position is tolerated only if a methoxy para substituent is present. These SAR findings were parallel to those obtained in the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine system. Enantioselectivity in enzyme recognition was observed and the activity resided in all cases only in one of the enantiomers.lld:pubmed
pubmed-article:11026540pubmed:languageenglld:pubmed
pubmed-article:11026540pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026540pubmed:citationSubsetIMlld:pubmed
pubmed-article:11026540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026540pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026540pubmed:statusMEDLINElld:pubmed
pubmed-article:11026540pubmed:monthSeplld:pubmed
pubmed-article:11026540pubmed:issn0968-0896lld:pubmed
pubmed-article:11026540pubmed:authorpubmed-author:MadsenPPlld:pubmed
pubmed-article:11026540pubmed:authorpubmed-author:JakobsenPPlld:pubmed
pubmed-article:11026540pubmed:authorpubmed-author:WestergaardNNlld:pubmed
pubmed-article:11026540pubmed:authorpubmed-author:VarmingA RARlld:pubmed
pubmed-article:11026540pubmed:authorpubmed-author:LundbeckJ MJMlld:pubmed
pubmed-article:11026540pubmed:issnTypePrintlld:pubmed
pubmed-article:11026540pubmed:volume8lld:pubmed
pubmed-article:11026540pubmed:ownerNLMlld:pubmed
pubmed-article:11026540pubmed:authorsCompleteYlld:pubmed
pubmed-article:11026540pubmed:pagination2277-89lld:pubmed
pubmed-article:11026540pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:meshHeadingpubmed-meshheading:11026540...lld:pubmed
pubmed-article:11026540pubmed:year2000lld:pubmed
pubmed-article:11026540pubmed:articleTitleGlucose-6-phosphatase catalytic enzyme inhibitors: synthesis and in vitro evaluation of novel 4,5,6,7-tetrahydrothieno[3,2-c]- and -[2,3-c]pyridines.lld:pubmed
pubmed-article:11026540pubmed:affiliationMedicinal Chemistry Research, Novo Nordisk A/S, Health Care Discovery, Målov, Denmark. pem@novo.dklld:pubmed
pubmed-article:11026540pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11026540lld:pubmed